|Bid||0.00 x 1400|
|Ask||0.00 x 900|
|Day's Range||23.00 - 24.06|
|52 Week Range||22.50 - 32.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.65|
GUANGZHOU, China, July 20, 2020 -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced that it plans to release its unaudited financial results for the second quarter of.
On June 29, 2020, Burning Rock Biotech Limited (BNR) announced a strategic partnership with CStone Pharmaceuticals (2616.HK) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients. CStone’s partner Blueprint Medicines released promising global data for pralsetinib this June at ASCO 2020.
GUANGZHOU, China, June 22, 2020 -- Burning Rock Biotech Limited (“Burning Rock” or the “Company”) (NASDAQ: BNR), a company focused on the application of next generation.